triple negative breast cancer
AZ, Daiichi take aim at Gilead in triple-negative breast cancer
Phil Taylor
antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, Gilead Sciences, Oncology, triple negative breast cancer, Trodelvy
0 Comment
Gilead moves closer to Chinese filing for Trodelvy in TNBC
Phil Taylor
China, Everest Medicines, Gilead Sciences, Oncology, triple negative breast cancer, Trodelvy
0 Comment
Gilead tags Merck for first-line triple negative breast cancer trial
Phil Taylor
Gilead Sciences, immuno-oncology, Keytruda, Merck & Co, Oncology, triple negative breast cancer, Trodelvy
0 Comment
Merck gets EU approval for Keytruda in triple-negative breast cancer
Phil Taylor
immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, Roche, Tecentriq, triple negative breast cancer
0 Comment
After false start, Merck claims Keytruda approval in early breast cancer
Phil Taylor
fda, immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, triple negative breast cancer
0 Comment
AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan
Richard Staines
breast cancer, cancer, triple negative breast cancer
0 Comment
Boehringer buys NBE for €1.18bn, adding cancer ADC expertise
Phil Taylor
antibody-drug conjugate, Boehringer Ingelheim, M&A, NBE-Therapeutics, Oncology, triple negative breast cancer
0 Comment
Immunomedics wows ESMO with breast cancer data reveal
Richard Staines
breast cancer, ESMO, Gilead, Immunomedics, Roche, triple negative breast cancer
0 Comment